EUROPEAN RESPIRATORY JOURNAL

Scope & Guideline

Shaping the Future of Respiratory Care

Introduction

Explore the comprehensive scope of EUROPEAN RESPIRATORY JOURNAL through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore EUROPEAN RESPIRATORY JOURNAL in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0903-1936
PublisherEUROPEAN RESPIRATORY SOC JOURNALS LTD
Support Open AccessNo
CountrySwitzerland
TypeJournal
Convergefrom 1988 to 2024
AbbreviationEUR RESPIR J / Eur. Resp. J.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND

Aims and Scopes

The European Respiratory Journal (ERJ) primarily focuses on advancing knowledge in respiratory medicine through high-quality research and clinical studies. Its scope encompasses a wide range of topics related to respiratory health, disease mechanisms, diagnostics, and therapeutic interventions.
  1. Pulmonary Disease Mechanisms:
    Research on the molecular and cellular mechanisms underlying various pulmonary diseases, including asthma, COPD, pulmonary fibrosis, and lung cancer.
  2. Clinical Guidelines and Practice:
    Development and dissemination of clinical practice guidelines for the management of respiratory conditions, ensuring evidence-based approaches in clinical settings.
  3. Innovative Therapies and Treatments:
    Exploration of novel therapeutic agents and treatment strategies, including biologics for severe asthma and personalized medicine approaches for chronic lung diseases.
  4. Epidemiology and Public Health:
    Studies focusing on the epidemiology of respiratory diseases, their risk factors, and public health implications, particularly in light of global health challenges such as the COVID-19 pandemic.
  5. Patient-Centered Research:
    Investigation of patient-reported outcomes, quality of life, and the psychosocial aspects of living with chronic respiratory diseases.
  6. Technological Advancements in Respiratory Medicine:
    Incorporation of innovative technologies, such as telemedicine and artificial intelligence, for improving patient care and outcomes in respiratory health.
The European Respiratory Journal has recently seen an increase in focus on several emerging themes that reflect the evolving landscape of respiratory medicine and public health.
  1. Long COVID and Post-Acute Sequelae:
    Research dedicated to understanding the long-term effects of COVID-19 on respiratory health, including pulmonary function and the management of post-COVID conditions.
  2. Personalized Medicine in Respiratory Care:
    A growing emphasis on tailoring treatments based on individual patient characteristics, particularly in managing chronic diseases like asthma and COPD.
  3. Artificial Intelligence and Digital Health:
    Emerging studies utilize artificial intelligence and digital health technologies to enhance diagnosis, treatment adherence, and patient monitoring in respiratory care.
  4. Environmental Impacts on Respiratory Health:
    Research exploring the effects of environmental factors, such as air pollution and occupational exposures, on respiratory diseases, emphasizing the need for public health interventions.
  5. Biologics and Targeted Therapies:
    Increased focus on the development and real-world application of biologics for severe asthma and other respiratory diseases, showcasing their effectiveness and safety in diverse populations.

Declining or Waning

While the European Respiratory Journal continues to cover a broad range of topics, certain areas of research appear to be declining in prominence based on recent publications.
  1. Traditional Pharmacotherapy:
    There is a noticeable shift towards biologics and targeted therapies, leading to less focus on traditional pharmacotherapy approaches, such as corticosteroids and bronchodilators.
  2. Basic Science Studies:
    Although foundational research remains important, there has been a growing preference for translational and clinical studies that directly impact patient care over purely basic science investigations.
  3. Epidemiological Studies in Stable Populations:
    Research focusing on stable populations without chronic diseases is becoming less frequent, with a pivot towards studies addressing exacerbations, long-term outcomes, and complications in chronic respiratory conditions.

Similar Journals

European Respiratory Review

Pioneering Discoveries in Respiratory Health
Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTDISSN: 0905-9180Frequency: 4 issues/year

European Respiratory Review is a prestigious peer-reviewed journal published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, specializing in the dynamic field of pulmonary and respiratory medicine. With an impact factor that places it among the top quartile journals in its category (Q1), as indicated by its impressive Scopus rank of #7 out of 155, it serves as a critical platform for disseminating high-quality research and innovative reviews in the field. As an Open Access journal since 2005, it ensures that cutting-edge findings are readily available to a global audience, promoting greater transparency and collaboration within the academic community. Published from Switzerland, European Respiratory Review covers a broad spectrum of topics from clinical advancements to emerging trends, making it an essential resource for researchers, healthcare professionals, and students committed to advancing respiratory health. The journal's history, dating back to 1992, reflects a steadfast commitment to fostering scholarly exchange and driving forward the frontiers of knowledge within respiratory medicine.

Tuberkuloz ve Toraks-Tuberculosis and Thorax

Empowering professionals with vital tuberculosis research.
Publisher: TURKISH ASSOC TUBERCULOSIS & THORAXISSN: 0494-1373Frequency: 4 issues/year

Tuberkuloz ve Toraks (Tuberculosis and Thorax) is a distinguished journal published by the TURKISH ASSOCIATION OF TUBERCULOSIS AND THORAX located in Turkey. Serving as a pivotal platform for researchers and practitioners in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, this journal has been disseminating vital research since 2003 and is committed to advancing knowledge and clinical practices related to tuberculosis and thoracic diseases. Although currently not an Open Access publication, its relevance is underscored by its rankings within Scopus, including a Q3 category in Critical Care and Intensive Care Medicine and a Q4 in Pulmonary and Respiratory Medicine, reflecting its significant contributions to the academic community. With a mission to foster the exchange of innovative ideas and encourage rigorous scholarly discourse, Tuberkuloz ve Toraks plays an essential role in addressing pressing health challenges associated with respiratory ailments and remains an invaluable resource for researchers, health professionals, and students dedicated to improving outcomes in thoracic health.

THORAX

Uncovering breakthroughs in lung health and disease.
Publisher: BMJ PUBLISHING GROUPISSN: 0040-6376Frequency: 12 issues/year

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

LUNG

Championing excellence in respiratory research and education.
Publisher: SPRINGERISSN: 0341-2040Frequency: 6 issues/year

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.

Tuberculosis and Respiratory Diseases

Exploring the frontiers of respiratory disease management.
Publisher: THE KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASESISSN: 1738-3536Frequency: 4 issues/year

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Lancet Respiratory Medicine

Elevating the standards of pulmonary medicine.
Publisher: ELSEVIER SCI LTDISSN: 2213-2600Frequency: 12 issues/year

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

PULMONARY PHARMACOLOGY & THERAPEUTICS

Connecting research to clinical excellence in pulmonary medicine.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1094-5539Frequency: 6 issues/year

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

Respiratory Investigation

Unlocking the future of respiratory health.
Publisher: ELSEVIERISSN: 2212-5345Frequency: 6 issues/year

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

Annals of the American Thoracic Society

Advancing pulmonary health through innovative research.
Publisher: AMER THORACIC SOCISSN: 1546-3222Frequency: 12 issues/year

Annals of the American Thoracic Society is a premier journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by the American Thoracic Society, this journal offers an invaluable platform for researchers and clinicians to disseminate cutting-edge research, clinical insights, and innovative methodologies. With an impressive impact factor and ranked in the top Q1 category of its field (2023) and within the top 20 of 155 according to Scopus rankings, it is positioned as a leading force in shaping clinical practice and research directions. The journal's convergence years from 2013 to 2024 indicate a commitment to providing timely and relevant content at the forefront of pulmonary health. While not an open-access journal, it ensures broad accessibility to its significant contributions in respiratory medicine, making it an essential resource for professionals, researchers, and students alike endeavoring to deepen their understanding and improve outcomes in thoracic health.

Annals of Thoracic Medicine

Fostering collaboration in the pursuit of thoracic excellence.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1817-1737Frequency: 4 issues/year

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.